There is increasing interest in the therapeutic utility of vitamin D in asthma, which is sup- 
starts with conversion in the skin of 7-dehydrocholesterol to vitamin D 3 in a reaction requiring solar ultraviolet B radiation, and reduced exposure to sunlight in our modern lifestyle is thought to be responsible for the high prevalence of vitamin D insufficiency. 1, 3 As part of evolving vitamin D research over the past 15 years, there has been intense interest in the role vitamin D may play in health and homeostasis of the airways, and the effect of vitamin D deficiency on pathologic conditions of the airways.
In this review, we discuss evidence for vitamin D insufficiency/deficiency contributing to the pathologic mechanisms of asthma and evidence that vitamin D supplementation should be considered part of the holistic treatment of asthma.
Epidemiologic research has revealed strong significant associations between diverse aspects of asthma and reduced levels of serum 25-hydroxyvitamin D (25[OH] D), the major circulating precursor, which is commonly used as a measure of vitamin D status. Cross-sectional studies have consistently found more severe asthma in patients with lower vitamin D levels. 4 Similar associations seen in other diseases have led to vigorous discussion about whether these associations are due to causation or reverse causation. Three streams of evidence strongly support a causation theory that reduced levels of circulating vitamin D can contribute to more severe asthma: (1) prospective epidemiologic evidence, (2) mechanistic research, and (3) vitamin D supplementation studies. Nevertheless, reverse causation (asthma itself leads to decreased vitamin D levels) is also likely to be true with reduced time spent outside in more severe asthma and the likelihood that asthmatic inflammation is vitamin D consumptive, as has been shown for other types of inflammation. 5 We propose that there is a complex relationship between vitamin D insufficiency and the pathologic mechanisms of asthma, with a vicious cycle of causation and reverse causation leading to progressive worsening of asthma and that this cycle may be broken by including vitamin D supplementation in asthma care. As discussed further on, this evidence supports a therapeutic role for vitamin D for secondary prevention in patients with asthma to reduce asthma exacerbations and also airway inflammation with remodeling.
Prospective Epidemiologic Evidence
Most vitamin D epidemiologic studies have been cross-sectional, comparing vitamin D levels to recent asthma control, and therefore more vulnerable to reverse causation. Few studies have compared vitamin D levels to future asthma control. However, Brehm et al 6 reported an association between baseline serum vitamin D status and the risk of a severe exacerbation over the following 4 years in children enrolled in the Childhood Asthma Management Program study. After adjustment for other variables, including physician-judged asthma severity, patients with baseline vitamin D insufficiency (< 30 ng/mL) had higher odds of an asthma exacerbation requiring hospitalization or ED attendance over the follow-up period.
Mechanistic Research
Translational research over the past 15 years has shown vitamin D to have a major role in regulating immunologic responses. Such a role is not surprising given the high frequency of vitamin D response elements in cells of the immune system such as CD4 T lymphocytes. 7 The immunology of asthma is complex and the disease heterogeneous; we are increasingly aware that multiple independent pathologic mechanisms can lead to asthmatic inflammation and that the relative contribution of the pathways will differ from individual to individual. These pathways interact; the subdivisions described in the following sections are meant to aid discussion. Importantly, vitamin D has beneficial actions at multiple steps in all these proposed pathways. Furthermore, chronic uncontrolled asthmatic inflammation may contribute to airway remodeling; this is also reduced by vitamin D, likely through its actions on structural cells, as discussed further on.
Aeroallergen Triggered Asthma
Classically, asthmatic inflammation was thought to be primarily due to antigen-dependent immune responses to aeroallergens, with T-helper (Th)2 lymphocytes, IgE-secreting B lymphocytes, and mast cells featuring prominently in this pathomechanism (Fig 1) . Naive T lymphocytes become inappropriately primed to respond to otherwise innocuous inhaled aeroallergens with Th2 polarity, and on restimulation by inhaled aeroallergens, they produce the Th2 cytokines interleukin (IL)-4, IL-5, and IL-13, which promote the pathologic mechanisms of asthma. IL-4 promotes class switching of B lymphocytes to IgE production. Aeroallergen-specific IgE is produced by these B lymphocytes and coats mast cells, and then on inhalation of aeroallergens, the IgE on mast cells becomes cross-linked, leading to rapid release of further proinflammatory asthma mediators, such as leukotrienes and histamine, which cause bronchoconstriction and airway mucus production. 20 These stimulated ILC2s then produce Th2-type cytokines, including IL-5, which in turn promotes eosinophilic inflammation (Fig 2) . Of these alarmins, IL-33 appears particularly important in asthma, with both its gene (IL33) and the gene for its chestjournal.org receptor (1L1RL1) identified in asthma genome wide association studies. 21 Vitamin D has been shown to modulate the epithelial response to stimulation, with a potentially antiinflammatory role for this action. 22 However, of specific relevance to asthma is the capacity of vitamin D to stimulate bronchial epithelial cell production of soluble ST2, a decoy blocker for IL-33, and for this epithelialproduced soluble ST2 to decrease the proinflammatory effect of IL-33 on target cells such as mast cells. 23 There is relatively little evidence about the effect of vitamin D on ILC2s and eosinophils. Ethier et al 24 showed vitamin D to be able to enhance eosinophil viability with reduced production of proinflammatory necrotic granules. Ruiter et al 25 showed vitamin D to reduce proinflammatory cytokine production by stimulated ILC2s.
Viral infections in particular trigger epithelial IL-33 release, 26 which is important given that Th2-biased pathologic mechanisms of asthma have been shown to impair appropriate antiviral immune responses. 27 Indeed, asthma exacerbations are frequently associated with viral respiratory tract infections. Vitamin D, however, enhances antimicrobial immune responses through many mechanisms. It enhances cellular production of antimicrobial peptides (such as cathelicidin) and autophagy, which are important in the response to both bacterial and viral infections. [28] [29] [30] Consistent with these actions of vitamin D, meta-analysis has shown vitamin D supplementation in appropriate patients reduces acute respiratory tract infections. 31 
Steroid-Resistant Asthma and IL-17
In a proportion of patients with the most severe asthma, the pathologic mechanism appears to have some distinct features, in particular corticosteroid resistance and an apparent pathologic role for IL-17 (Fig 3) . Multiple pathways to steroid resistance in airway disease have been described. 32 Airway colonization with proinflammatory bacteria such as Haemophilus influenzae, oxidative stress (eg, from air pollution), and vitamin D deficiency itself are major contenders for causing acquired steroid resistance in asthma. Vitamin D enhances antimicrobial pathways and vitamin D also promotes antioxidant responses. 33 Additionally, vitamin D ameliorates steroid-resistant inflammation through its direct actions on lymphocytes (discussed further on) and monocytes. 34 Steroid-insensitive patients with asthma have impaired steroid-induced production of antiinflammatory IL-10. In vitro, vitamin D enhances steroid-induced lymphocyte production of IL-10, and supplementation with the calcitriol form of vitamin D in patients with steroid-resistant asthma restores both the clinical and immunologic IL-10 response to corticosteroids. [35] [36] [37] Furthermore, we have shown that corticosteroids actually promote production of IL-17 in steroid-resistant individuals; in this context, the IL-17 is thought to cause pathologic neutrophilic inflammation, which ameliorates after vitamin D supplementation. 37 Subramanian et al 38 recently reported that vitamin D reduced production of proinflammatory cytokines by stimulated neutrophils. However, vitamin D enhanced the antibacterial activity of neutrophils through enhanced production of antimicrobial peptides rather than increased production of elastase or reactive oxygen species. 38 These findings are consistent with earlier findings of vitamin D responsiveness of neutrophils reported by Takahashi et al. 39 
Vitamin D and Airway Remodeling
The downstream effect of asthmatic immune responses, regardless of the mechanisms precipitating those responses, is airway narrowing. Over the short-term, this is due to smooth muscle constriction and mucus secretion, whereas over the longer-term, airway remodeling and fibrosis occur. Importantly, vitamin D has actions on airway smooth muscle that include inhibiting airway smooth muscle cell proliferation. 40, 41 Consistent with this, Gupta et al 14 43 One possible explanation for the divergent results is underpowering in some studies and smaller effect sizes than anticipated. However, we believe that differences and limitations in study design partly explain the differences in study outcome (Table 1) . [44] [45] [46] [47] [48] These methodological issues in vitamin D treatment trials are not specific to asthma and are worthy of detailed discussion.
First, is vitamin D supplementation beneficial in all patients or only when it corrects low vitamin D levels in deficient patients? Unlike trials of pharmacologic drugs, in trials of vitamins, patients at baseline have variable circulating levels of the vitamins and will have variable natural intake over the course of the trial through their normal activities of daily living. Subgroup analyses in two studies of vitamin D as a treatment for COPD showed a 
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A major limitation of some studies may therefore be that many participants had relatively sufficient vitamin D levels at baseline and were less likely to benefit.
Not all supplemented patients in the treatment arms of these trials actually achieved vitamin D sufficiency during the trials. However, the fact that supplementation does achieve vitamin D sufficiency appears an important determinant of benefit. In the VIDA trial, approximately one fifth of participants in the vitamin D 3 treatment arm did not achieve a serum 25(OH)D 3 level $ 30 ng/mL (equivalent to approximately 75 nmol/L). Although the rate of exacerbations was not significantly decreased in the overall treatment group compared with the placebo group, an exploratory responder analysis showed that when those not achieving a 25(OH)D 3 level $ 30 ng/ mL in the treatment arm were excluded, there was a significant reduction in exacerbations in the treatment arm compared with the placebo arm. ). In particular, bolus vitamin D supplementation (as used in some asthma studies) may be immunologically problematic, causing large swings in serum levels and inducible homeostatic enzymes, with dysregulation of other vitamin D-regulated pathways. 56 Indeed a recent meta-analysis of trials of vitamin D to prevent acute respiratory tract infections found regimens with regular vitamin D dosing to be associated with a protective action of vitamin D but regimens with high-dose boluses to not show protective effect. 31 The most common forms of vitamin D for supplementation are ergocalciferol (vitamin D 2 ) and cholecalciferol (vitamin D 3 ); although there is little research on ergocalciferol supplementation in asthma, by extrapolating from other diseases, cholecalciferol is more likely to be beneficial than is ergocalciferol. 57 Finally, correction of vitamin D insufficiency through increased exposure to ultraviolet radiation may be more physiologically appropriate and more effective in asthma than oral supplementation. 58 Third, vitamin D supplementation may be more beneficial in pediatric asthma 44, 48 Fourth, although the mechanistic studies cited show the capacity of vitamin D to beneficially modulate the different pathways thought to underlie different asthma endotypes, it is possible that some of these actions of vitamin D have little clinical efficacy. Therefore vitamin D therapies may be particularly beneficial in discrete endotypes of asthma. The larger RCTs have not selected for specific asthma endotypes; however, we have shown evidence for a particular role for vitamin D therapy in a severe steroid-resistant asthma endotype. 36, 37 Further large studies of daily vitamin D supplementation to improve asthma control in vitamin D-deficient asthmatic children and adults are needed to better understand these issues. Nevertheless, there is increasing realization that vitamin D deficiency has a negative impact on general health status and that vitamin D supplementation rarely has side effects. Therefore, optimizing vitamin D status is increasingly becoming part of standard holistic clinical care in asthma (Table 2 ).
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Vitamin D in Early Life and Primary Prevention of Asthma
Vitamin D deficiency and insufficiency are extremely common in pregnancy and are associated with chestjournal.org pre-eclampsia, gestational diabetes mellitus, and other comorbidities of pregnancy. 60 It has also been associated with increased respiratory infections and asthma in the newborn and children in many studies. 61 Vitamin D is proposed to have a beneficial impact on fetal and neonatal lung maturation, as well as immunity in a manner likely to promote maternal-fetal tolerance and to protect mother and fetus from infection. 61, 62 Importantly, these associations between maternal vitamin D insufficiency and asthma in the offspring cannot be explained as being due to reverse causation, although an effect of unmeasured confounding variables in these studies is possible.
The mechanisms by which vitamin D in early life could help reduce the development of asthma include (1) its capacity to support development of tolerogenic immune responses (as discussed earlier), (2) its facilitation of appropriate antiviral and antibacterial immune responses, (3) its enhancement of barrier properties of the epidermis and the decrease of eczema, and (4) its enhancement of appropriate lung development, which are all factors important in determining whether an individual acquires symptomatic chronic airway disease. 63 In particular, in utero vitamin D has been shown to affect the expression of genes that are important in early pulmonary development (eg, branching morphogenesis) and to influence multiple aspects of later lung development, including alveolar development and surfactant secretion. during the second and third trimesters and reported a significant reduction in allergic sensitization and a trend for a reduction in recurrent wheezing and asthma in the offspring through 3 years. Importantly, no increase in adverse effects was reported in these or other comparable pregnancy studies. 60, 66, 67 In an ancillary study of cord blood samples from a subset of babies born to women in the VDAART cohort, Hornsby et al 68 showed that supplementation significantly enhanced proinflammatory cytokine responses to mitogen and Tolllike receptor (TLR) agonist stimulation and increased TLR2 and TLR9 gene expression and IL-17A secretion in response to T-cell receptor ligation. Thus, vitamin D supplementation during pregnancy modifies the immune system of the neonate in a manner that is predicted to protect the host against pathogenic infections and reduce the development of asthma. In support of these conclusions secondary principle component analysis within the COPSAC study reported an upregulated neonatal airway In addition, similar to the secondary prevention trials, not all patients in these primary prevention trials achieved vitamin D sufficiency despite high-dose supplementation (75% in the VDAART trial and 81% in the COPSAC trial). 66, 67 This underscores the likelihood that different individuals require different doses of vitamin D to achieve sufficiency; however, both trials did note that a significant proportion of participants were not adequately adherent to the vitamin D intervention. Previously, infrequent bolus dosing of vitamin D supplements has been suggested as a strategy to improve adherence, but as we already discussed, such infrequent bolus dosing may be immunologically problematic.
It is also too early to determine whether high-dose vitamin D supplementation in these primary prevention studies has successfully reduced the proportion of children going on to experience asthma; reported followup to date is for up to 3 years of age, whereas asthma is often diagnosed slightly later in childhood. Long-term follow-up of these patients is eagerly awaited.
The longitudinal effects of vitamin D during the first 10 years of life were investigated in a high-risk Australian cohort to determine relationships between 25(OH)D levels and susceptibility to allergic sensitization, respiratory tract infections, and asthma. 71 The study showed that 25(OH)D deficiency in early childhood is associated with increased risk for persistent asthma. The authors proposed that vitamin D may act by influencing susceptibility to early allergic sensitization or upper respiratory tract colonization with bacterial pathogens, or both.
Together, these very recent studies bring real enthusiasm to the investigation of strategies that restore vitamin D sufficiency in pregnancy and the first years of life, which offers the potential to reduce both important asthma risk factors, namely, allergic sensitization and respiratory tract infection, as well as asthma itself. A future challenge will be to determine safe and effective regimens of vitamin D 3 supplementation in the newborn and infant.
Conclusions
There is a wealth of epidemiologic evidence of a detrimental association between vitamin D insufficiency and asthma, and translational studies have shown vitamin D to have the capacity to beneficially regulate diverse aspects of the pathologic mechanisms of asthma. Methodological considerations with vitamin D RCTs to date may underlie less impressive than hoped clinical effects in the trials. Further clinical trials, with revised protocols learning from the issues discussed in this paper, are needed. Nevertheless, the evidence base increasingly supports vitamin D supplementation as a safe, practical, and beneficial part of the comprehensive management of asthma.
